Patient capital,
plainly stated.

The philosophy.

Markets, by their nature, misprice securities for reasons that are neither rare nor mysterious. Investors crowd into narratives. Committees prefer the comfort of consensus. Cyclical anxieties are routinely confused with structural decline. Our work begins where that confusion is most pronounced — in businesses whose competitive advantages are durable, whose capital allocation is rational, and whose valuations reflect a short-term concern rather than a long-term truth.

We write for ourselves first. Every position begins as a written thesis, defended against its own strongest counter-arguments before a single share is owned. The archive you see here is the uncensored record of that discipline — not because we are certain, but because we believe research without accountability is merely opinion.

The goal is not to be early, nor to be clever. It is to be right over a long enough horizon that the market has no choice but to agree.

The criteria.

We look for the same handful of qualities in every prospective investment. They are neither novel nor proprietary — which is precisely why we trust them.

• Durable competitive advantage. A moat that can be articulated in a sentence and defended in an hour.
• Rational capital allocation. Management that treats shareholder capital as its own — because, often, it is.
• Structural tailwinds, not cyclical hope. Demand curves shaped by decades, not quarters.
• Margin of safety, honestly derived. Valuation anchored to conservative cash flows, not to the generosity of multiples.

The method.

Each thesis is developed through a process that has changed little since the practice was founded. We read primary documents — annual reports, transcripts, regulatory filings — before reading any secondary analysis. We construct our own models from scratch rather than inheriting spreadsheets. We interview former employees, customers, and competitors when the situation warrants. And we write, at length, about what we believe, why we believe it, and precisely what would cause us to change our minds.

Financial modelling is the quiet discipline beneath everything else. Discounted cash flow analysis, scenario planning, and sensitivity tables are not presented as science — they are presented as honest arithmetic under stated assumptions. When the assumptions are wrong, we say so.

The mandate.

Our work spans public equities without geographic prejudice. We have a particular affinity for technology and semiconductors, financial services, healthcare, and the overlooked industrial economies of emerging markets — less because they are fashionable than because they are often misunderstood.

All research is conducted independently, represents the personal views of the author, and is published without commercial obligation. This is not investment advice. It is, in the oldest sense of the phrase, a letter to a thoughtful reader.